Table 1:
Characteristics of the study populations
| Characteristics | BREATHE | ESTATe | Follow MAGICS | GALA II | PACMAN | PAGES | PASS | SAGE | SLOVENIA | SCSGES |
|---|---|---|---|---|---|---|---|---|---|---|
| n | 998 | 101 | 167 | 1,618 | 791 | 722 | 384 | 740 | 212 | 170 |
| Male sex, % | 60.0 | 58.0 | 62.3 | 55.7 | 62.3 | 57.6 | 56.0 | 52.3 | 56.1 | 68.2 |
| Mean age, y (SD) | 10.2 (4.0) | 10.6 (4.2) | 17.3 (3.0) | 12.4 (3.2) | 8.7 (2.3) | 9.8 (3.7) | 11 (3.3) | 13.8 (3.5 ) | 10.8 (3.4) | 14.0 (6.4) |
| Ethnicity, n. (%) | ||||||||||
| Caucasian | 998 (100) | 96 (95) | 167 (100) | N/A | 711 (89.9) | 360 (50) | 384 (100) | N/A | 212 (100) | N/A |
| Hispanic | N/A | N/A | N/A | 1,618.(100) | 3 (0.4) | N/A | N/A | 744 (100) | N/A | N/A |
| Asian | N/A | 1 (1) | N/A | N/A | 6 (0.8) | 11 (1.5) | N/A | N/A | N/A | 170 (100) |
| African | N/A | 0 (0) | N/A | N/A | 9 (1.1) | N/A | N/A | N/A | N/A | N/A |
| Mixed | N/A | 2 (2) | N/A | N/A | 53 (6.7) | 15 (2) | N/A | N/A | N/A | N/A |
| Unknown (missing) | N/A | 2 (2) | N/A | N/A | 9 (1.1) | 336 (46.5) | N/A | N/A | N/A | N/A |
| Treatment group, n. (%) | ||||||||||
| SABA alone | 173 (17.3) | 0 (0.0) | 25 (15.0) | 576 (35.6) | 80 (10.1) | 79 (10.9) | 0 (0.0) | 207 (27.9) | N/A | N/A |
| ICS alone | 562 (56.3) | 65 (64.0) | 39 (23.3) | 538 (33.2) | 497 (62.8) | 271 (37.6) | 29 (7.5) | 367 (49.6) | 212 (100) | 170 (100) |
| ICS + LABA | 142 (14.3) | 34 (34.0) | 84 (50.3) | 165 (10.2) | 148 (18.7) | 135 (18.7) | 126 (33.0) | 98 (13.2) | N/A | N/A |
| ICS + LTRA | 37 (3.7) | 0 (0.0) | 4 (2.4) | 208 (12.9) | 21 (2.7) | 65 (9.0) | 0 (0.0) | 35 (4.7) | N/A | N/A |
| ICS + LABA + LTRA | 84 (8.4) | 2 (2.0) | 15 (9.0) | 131 (8.1) | 45 (5.7) | 172 (23.8) | 229 (59.5) | 33 (4.6) | N/A | N/A |
| Asthma exacerbations in the past year or in the last six months prior to the study visit/enrolment | ||||||||||
| Hospitalizations/ED*, n. (%)# | 147 (14.7) | 13 (12.9) | 11 (6.6) | 865 (54.8) | 42 (5.5) | 151 (21.7) | 290 (75.5) | 272 (39.0) | 49 (27.7) | 34 (20.0) |
| OCS use*, n. (%)# | 234 (23.4) | 36 (35.6) | N/A | 587 (37.4) | 46 (5.8) | 316 (45.7) | 198 (51.6) | 162 (22.4) | 23 (12.9) | 36 (21.2) |
| Asthma exacerbations*, n. (%)# | 250 (25.0) | 49 (48.5) | N/A | 1,013 (64.3) | 75 (9.7) | 346 (50.0) | 331 (86.2) | 317 (45.8) | 54 (30.3) | 59 (34.7) |
N/A. Not Applicable
ED, emergency department visits; OCS use, oral corticosteroids use; Asthma exacerbations, asthma-related hospitalizations/ED visits or oral corticosteroids use.
Data on asthma-related hospitalizations/ED visits outcomes were missing in 40 subjects in GALA II, 24 subjects in PACMAN, 27 subjects in PAGES, 43 subjects in SAGE, and 35 subjects in SLOVENIA; data on asthma-related oral OCS use were missing in 49 subjects in GALA II, 30 subjects in PAGES, 16 subjects in SAGE, and 34 subjects in SLOVENIA, data on asthma exacerbations were missing in 44 subjects in GALA II, 21 subjects in PACMAN, 30 subjects in PAGES, 48 subjects in SAGE, and 34 subjects in SLOVENIA. In followMAGICS, only data on asthma-related hospitalizations/ED visits were available.